Provider Briefing: Acetylcysteine Supply in 2026

For clinicians who prescribe Acetylcysteine — whether in emergency departments managing acetaminophen toxicity, pulmonology clinics treating chronic lung disease, or critical care settings — understanding the current supply landscape is essential for patient care. This briefing covers the shortage timeline, current availability, prescribing considerations, and tools to help your patients access this medication.

Shortage Timeline

Acetylcysteine (N-Acetylcysteine, NAC) has had one of the longest shortage histories in the ASHP database:

• June 2011: ASHP first listed Acetylcysteine oral and inhalation solution as in shortage.
• 2011–2024: Intermittent supply disruptions persisted across multiple manufacturers and formulations, including the IV form (Acetadote). Manufacturing quality issues, facility shutdowns, and demand spikes contributed to recurring gaps.
• 2021: The FDA's challenge to NAC's status as a dietary supplement created additional market disruption, briefly removing OTC NAC products from major retailers like Amazon.
• 2022: FDA issued draft guidance clarifying that NAC-containing supplement products could remain on the market, stabilizing the OTC segment.
• September 2025: ASHP updated the shortage status to resolved. All marketed presentations of Acetylcysteine oral and inhalation solution were reported as available, including products from Somerset Therapeutics (NDC 70069-0019-25) and other manufacturers.

Prescribing Implications

While the formal shortage is resolved, several prescribing considerations remain relevant:

Emergency Use (Acetaminophen Overdose)

NAC remains the only FDA-approved antidote for potentially hepatotoxic acetaminophen ingestion. The IV protocol (Acetadote) is the standard of care in most emergency departments:

• Loading dose: 150 mg/kg IV over 60 minutes
• Second infusion: 50 mg/kg IV over 4 hours
• Third infusion: 100 mg/kg IV over 16 hours

The oral protocol (140 mg/kg loading, then 70 mg/kg every 4 hours for 17 doses) remains an alternative, particularly when IV access is limited or the IV form is temporarily unavailable. Oral administration may be complicated by vomiting; antiemetics (ondansetron) are often coadministered.

There are no therapeutic substitutes for NAC in acetaminophen toxicity. If your facility's supply is low, coordinate with pharmacy to ensure emergency stock is prioritized.

Mucolytic Therapy

For patients receiving nebulized Acetylcysteine for mucus management in cystic fibrosis, COPD, bronchiectasis, or chronic bronchitis, consider the following:

• Both 10% and 20% inhalation solutions are available. If one concentration is backordered, the other may be in stock — adjust dosing volumes accordingly.
• Pre-treatment with a bronchodilator (e.g., albuterol) is recommended, as nebulized Acetylcysteine can trigger bronchospasm, particularly in asthmatic patients.
• For patients who cannot tolerate or access Acetylcysteine, evidence-based alternatives include Dornase Alfa (Pulmozyme) for CF, hypertonic saline (3% or 7%), and Guaifenesin for milder cases.

Current Availability Picture

As of early 2026, the supply landscape includes:

• Inhalation solutions (10% and 20%): Available from multiple manufacturers. Pricing starts at approximately $14 for 30 mL (10%) and $22 for 90 mL (20%).
• IV solution (Acetadote, 20%): Available from Cumberland Pharmaceuticals and generic manufacturers. Pricing ranges from $101 to $206 for 120 mL.
• Oral capsules/tablets (NAC, 500–600 mg): Widely available OTC as dietary supplements, typically $10–$25 for 60–100 count.

Pharmacies may still show variability in stock levels. Hospital pharmacies should maintain emergency reserves of the IV formulation for acetaminophen overdose cases.

Cost and Access Considerations

Acetylcysteine is available as a generic, which keeps costs relatively manageable. However, cost barriers may still affect outpatient access:

• Insurance coverage: Most commercial and Medicare plans cover the prescription formulations. The inhalation solution may require prior authorization for outpatient nebulizer use.
• No manufacturer savings programs: Unlike branded medications, there are no copay cards or manufacturer discount programs for Acetylcysteine.
• Patient assistance: No dedicated PAPs exist, but patients can access general programs through NeedyMeds, RxAssist, or pharmacy discount cards (SingleCare, GoodRx).
• OTC NAC: For patients using NAC as an antioxidant supplement (off-label), the OTC form is not covered by insurance and costs $10–$25 out of pocket.

Tools and Resources for Your Practice

Help your patients navigate access challenges with these resources:

• Medfinder for Providers: A tool that helps locate pharmacies with specific medications in stock. Share the link with patients or use it during clinical encounters to confirm availability before prescribing.
• ASHP Drug Shortage Database: Monitor the ASHP shortage list for real-time updates on Acetylcysteine and other medications.
• Compounding pharmacies: For patients who need specific concentrations or formulations not commercially available, compounding may be an option.

For a patient-facing version of this information, direct patients to our guides on the Acetylcysteine shortage update and how to find Acetylcysteine in stock.

Looking Ahead

The multi-manufacturer generic market for Acetylcysteine provides more supply resilience than in previous years. However, the drug's long shortage history is a reminder that vigilance is warranted. Facilities should:

• Maintain minimum safety stock for the IV formulation
• Have protocols in place for switching between IV and oral NAC protocols when necessary
• Educate pharmacy staff on alternative mucolytic agents
• Consider proactive patient communication when supply disruptions are anticipated

Final Thoughts

The Acetylcysteine supply situation has improved substantially heading into 2026, but its 14-year shortage history warrants continued attention. By staying informed on supply status, maintaining flexible prescribing practices, and using tools like Medfinder for Providers, you can ensure your patients maintain access to this essential medication.

For additional provider resources, see our companion guide: How to help your patients find Acetylcysteine in stock. For cost-related guidance, read how to help patients save money on Acetylcysteine.